3D-DXA reveals significant effects of burosumab on trabecular and cortical skeletal envelopes in symptomatic adults with X-linked hypophosphatemia
Authors' conclusion
These data demonstrate that burosumab increases both cortical and trabecular bone in the hip, a site of frequent fracture in XLH.
Study context
- Population
- Symptomatic adults with X-linked hypophosphatemia (XLH), volunteers from the registration trial for burosumab
- Participants
- 20 adults
- Comparison
- Burosumab: end of treatment vs baseline
- Burosumabn = 20
Methodological details3D-DXA analysis, DXA hip scans before and 6, 12 and 18-24 mo after therapy; 3D-Shaper software
- 3D-DXA analysis
- DXA hip scans before and 6, 12 and 18-24 mo after therapy; 3D-Shaper software
Primary result
As reported in the abstract
Trabecular vBMD change from baseline · end of treatment
TH trabecular volumetric BMD (vBMD) increase vs baseline (p < .0001)
13.6%
FN trabecular vBMD increase vs baseline (p < .0001)
14.1%
Further findings
FN cortical surface BMD (sBMD)
- Significant increase between 6 and 12 mo
- P < 0.05
- Significant increase between 6 and 18-24 mo
- P < 0.05
FN cross-sectional moment of inertia (CSMI) (indicator of FN strength) vs baseline
- Significant increase at 12 mo
- P < 0.05
- Significant increase at 18-24 mo
- P < 0.01
Original publication
3D-DXA reveals significant effects of burosumab on trabecular and cortical skeletal envelopes in symptomatic adults with X-linked hypophosphatemia. J Bone Miner Res. Published 13 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →